

### **Kniss Laboratories Private Limited**

January 28, 2025

Facilities/Instruments	Amount (₹ crore)	Rating <sup>1</sup>	Rating Action	
Long Term Bank Facilities	4.50	CARE D; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category	
Long Term / Short Term Bank Facilities	3.50	CARE D / CARE D; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category	
Short Term Bank Facilities	2.00	CARE D; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category	

Details of instruments/facilities in Annexure-1

### Rationale and key rating drivers

CARE Ratings Ltd. had, vide its press release dated January 09, 2024, placed the rating(s) of Kniss Laboratories Private Limited (KLPL) under the 'issuer non-cooperating' category as KLPL had failed to provide information for monitoring of the rating as agreed to in its Rating Agreement. KLPL continues to be non-cooperative despite repeated requests for submission of information through e-mails dated November 24, 2024, December 04, 2024 and December 14, 2024 among others.

In line with the extant SEBI guidelines, CARE Ratings Ltd. has reviewed the rating on the basis of the best available information which however, in CARE Ratings Ltd.'s opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

Analytical approach: Standalone

Outlook: Not applicable

### **Detailed description of the key rating drivers:**

Please refer to PR dated January 09, 2024

## **Applicable criteria**

<u>CARE Ratings' criteria on information adequacy risk and issuer non-cooperation</u>
Policy on default recognition

### **About the company**

Kniss Laboratories Private Limited (KLPL) was established in 1989 and it was converted into a Private Limited Company on November 17, 1998. KLPL is engaged in manufacturing and marketing of allopathic and ayurvedic formulations. The company procures its major raw materials like Paracetamol and vitamins from local suppliers and exports the same to various countries in Asia and Africa apart from selling it domestically within India. The company markets its drugs in the name of Kniss Laboratories Private Limited. The registered office of the company is located at Ashok Nagar, Chennai and the manufacturing unit is located at Gerugambakkam, Chennai.

**Status of non-cooperation with previous CRA:** CRISIL has continued the rating assigned to the bank facilities of KLPL under Issuer Not Cooperating category vide press release dated January 22, 2024 on account of its inability to carry out a review in the absence of the requisite information from the company.

Any other information: Not Applicable

Rating History for last three years: Annexure-2

Covenants of rated instrument/facility Annexure-3

<sup>1</sup>Complete definition of the ratings assigned are available at <u>www.careedge.in</u> and other CARE Ratings Ltd.'s publications.

<sup>\*</sup>Issuer did not cooperate; based on best available information



Complexity level of various instruments rated: Annexure-4

Lender details: Annexure 5

**Annexure-1: Details of Instruments/Facilities** 

Name of the Instrument	ISIN	Date of Issuance (DD- MM-YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Fund-based - LT-Cash Credit		-	-	-	3.00	CARE D; ISSUER NOT COOPERATING*
Fund-based - LT-Term Loan		-	-	April 2023	1.50	CARE D; ISSUER NOT COOPERATING*
Fund-based - ST-Bill Discounting/ Bills Purchasing		-	-	-	2.00	CARE D; ISSUER NOT COOPERATING*
Non-fund-based - LT/ ST-BG/LC		-	-	-	3.50	CARE D / CARE D; ISSUER NOT COOPERATING*

<sup>\*</sup>Issuer did not cooperate; Based on best available information



Annexure-2: Rating History of last three years

Ann	Annexure-2: Rating History of last three years							
	Name of the Instrument/ Bank Facilities	Current Ratings			Rating History			
Sr. No.		Туре	Amount Outstandin g (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Fund-based - LT- Cash Credit	LT	3.00	CARE D; ISSUER NOT COOPERATI NG*	-	1)CARE D; ISSUER NOT COOPERATI NG* (09-Jan-24)	1)CARE D; ISSUER NOT COOPERATI NG* (17-Nov-22) 2)CARE B-; Stable; ISSUER NOT COOPERATI NG* (21-Sep-22)	1)CARE B-; Stable; ISSUER NOT COOPERATI NG* (21-Jul-21)
2	Fund-based - LT- Term Loan	LT	1.50	CARE D; ISSUER NOT COOPERATI NG*	-	1)CARE D; ISSUER NOT COOPERATI NG* (09-Jan-24)	1)CARE D; ISSUER NOT COOPERATI NG* (17-Nov-22) 2)CARE B-; Stable; ISSUER NOT COOPERATI NG* (21-Sep-22)	1)CARE B-; Stable; ISSUER NOT COOPERATI NG* (21-Jul-21)
3	Fund-based - ST- Bill Discounting/ Bills Purchasing	ST	2.00	CARE D; ISSUER NOT COOPERATI NG*	-	1)CARE D; ISSUER NOT COOPERATI NG* (09-Jan-24)	1)CARE D; ISSUER NOT COOPERATI NG* (17-Nov-22) 2)CARE A4; ISSUER NOT COOPERATI NG* (21-Sep-22)	1)CARE A4; ISSUER NOT COOPERATI NG* (21-Jul-21)
4	Non-fund-based - LT/ ST-BG/LC	LT/ST	3.50	CARE D / CARE D; ISSUER NOT COOPERATI NG*	-	1)CARE D / CARE D; ISSUER NOT COOPERATI NG* (09-Jan-24)	1)CARE D / CARE D; ISSUER NOT COOPERATI NG* (17-Nov-22) 2)CARE B-; Stable / CARE A4; ISSUER NOT COOPERATI NG* (21-Sep-22)	1)CARE B-; Stable / CARE A4; ISSUER NOT COOPERATI NG* (21-Jul-21)

<sup>\*</sup>Issuer did not cooperate; Based on best available information LT: Long term; ST: Short Term; LT/ST: Long term/Short Term

Annexure-3: Detailed explanation of the covenants of the rated instruments/facilities: Not Applicable



Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level		
1	Fund-based - LT-Cash Credit	Simple		
2	Fund-based - LT-Term Loan	Simple		
3	Fund-based - ST-Bill Discounting/ Bills Purchasing	Simple		
4	Non-fund-based - LT/ ST-BG/LC	Simple		

# **Annexure-5: Lender details**

To view the lender wise details of bank facilities please click here

**Note on complexity levels of the rated instrument:** CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to <a href="mailto:care@careedge.in">care@careedge.in</a> for any clarifications.



## **Contact us**

#### **Media Contact**

Mradul Mishra Director

**CARE Ratings Limited** Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

#### **Relationship Contact**

Ankur Sachdeva Senior Director

CARE Ratings Limited Phone: 91 22 6754 3444

E-mail: Ankur.sachdeva@careedge.in

### **Analytical Contacts**

Shachee Vyas Assistant Director

CARE Ratings Limited Phone: 079-40265665

E-mail: shachee.tripathi@careedge.in

Aniket Shringarpure Lead Analyst

CARE Ratings Limited
Phone: +91-079-40265659

E-mail: aniket.shringarpure@careedge.in

Rajvi Jani Associate Analyst CARE Ratings Limited E-mail: Rajvi.jani@careedge.in

#### **About us:**

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India (SEBI), it has also been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates to raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages our domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments including commercial papers, corporate bonds and debentures, and structured credit.

#### Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

\*\*For the detailed Rationale Report and subscription information, please contact us at www.careedge.in